BRAF and non-small cell lung carcinoma: Such treatments were considered in 15 of the 23 NSCLC dossiers for the following mutations: anaplastic lymphoma kinase (ALK), rapidly accelerated fibrosarcoma-isoform B (BRAF), epidermal growth factor receptor (EGFR) and the C-ros oncogene 1 (ROS1).